Olivier Danos

Company: REGENXBIO

Job title: Chief Scientific Officer

Seminars:

Case Study: Advancing Treatment for Rare Neuromuscular Diseases through Gene Therapy – Inside REGENXBIO’s Pipeline 2:30 pm

•    Leveraging the NAV AAV platform to develop gene therapies for rare neuromuscular diseases, aiming to provide long-lasting, single administration treatments •    Highlighting leading candidates in development to address conditions like Duchenne muscular dystrophy DMD, with innovative approaches that target underlying genetic causes Read more

day: Day 1- Clinical 2